Abstract:Introduction α-Fodrin is an autoantigen in Sjögren's syndrome. We hypothesized that mucosal administration of α-fodrin might prevent the disease. Methods Four-week-old NOD mice were immunized (intranasal) with a 1 μg or 10 μg dose of α-fodrin every other day. PBS 10 μl/dose and Glutathione transferase (GST 10 μg/dose (control mice) were intranasally administrated by the same procedure. The salivary flow was maintained in immunized animals. The animals were analyzed for the presence of anti-Sjögren's syndrome A, anti-Sjögren's syndrome B, rheumatoid factor and antinuclear, anti-α-fodrin, and anti-type 3 muscarinic acetylcholine receptor polypeptide (anti-M3RP) by immunofluorescence or ELISA. The cytokines IFNγ and IL-10 were measured by ELISA. Salivary glands were examined by H&E staining and immunohistochemical analysis. The water-volume intake was calculated for each group. The induction of regulatory T cells was assessed by fluorescence-activated cell sorting analysis for the frequency of Foxp3 + cells among peripheral CD4 + CD25 + T cells. Results The appearance of anti-α-fodrin and anti-M3RP antibodies was delayed in mice immunized with α-fodrin. The titers of anti-α-fodrin and anti-M3RP antibodies were lower in immunized mice ( P < 0.05), but there was no significant difference between the low-dose or high-dose immunization groups. Five out of eight mice in the GST group, five of eight mice in the PBS group, two of eight mice in the α-fodrin 1 μg/dose group, and three out of eight mice in the α-fodrin 10 μg/dose were positive for antinuclear antibodies. The levels of serum IFNγ in mice immunized with 1 μg/dose or 10 μg/dose α-fodrin, with PBS, and with GST were 41.9 ± 16.2 pg/ml, 37.1 ± 15.4 pg/ml, 86.8 ± 17.8 pg/ml and 71.6 ± 11.1 pg/ml, respectively, while we found no difference in the levels of serum IL-10 among the groups. The number of Foxp3 + CD4 + CD25 + regulatory T cells was higher in the α-fodrin groups compared with the PBS and GST control groups ( P < 0.05). Lymphocytic infiltration and expression of α-fodrin in the salivary glands was decreased in α-fodrin-treated groups. The fluid intake of mice in the 1 μg/dose α-fodrin, 10 μg/dose α-fodrin, PBS, and GST groups was 39.2 ± 2.1 ml, 40.4 ± 2.5 ml, 49.3 ± 3.1 ml and 51.6 ± 2.8 ml, respectively. Conclusion Mucosal administration of α-fodrin effectively inhibited the progression of experimental Sjögren's syndrome autoimmunity.

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome–Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice

Effect of Nourishing Yin, Strengthening Qi and Activating Blood Decoction on Fas/FasL in Salivary Glands of NOD Mice with Sjogren's Syndrome and Their Mrna Expression

Sphingosine-1-phosphate Alleviates Sjögren’s Syndrome-Like Symptoms Via Inducing Autophagy and Regulating Status of Treg Cells in NOD Mice

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Ppar-Alpha Agonist Fenofibrate Suppressed The Formation Of Ocular Surface Squamous Metaplasia Induced By Topical Benzalkonium Chloride

Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Fenofibrate Inhibited the Differentiation of T Helper 17 Cells in Vitro

Fosfenopril Attenuates Inflammatory Response in Diabetic Dry Eye Models by Inhibiting the TLR4/NF-κB/NLRP3 Signaling Pathway

AS101 regulates the Teff/Treg balance to alleviate rabbit autoimmune dacryoadenitis through modulating NFATc2

Fty720 Ameliorates Dry Eye Disease in Nod Mice: Involvement of Leukocytes Inhibition and Goblet Cells Regeneration in Ocular Surface Tissue

Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice

Fenofibrate Inhibits Subretinal Fibrosis Through Suppressing TGF‐β—Smad2/3 signaling and Wnt signaling in Neovascular Age‐Related Macular Degeneration

De Novo Fatty Acid Synthesis Induced Sjogren's Syndrome by Promoting Th17 Differentiation

The Polysaccharide from Dendrobium officinale Can Improve Mice with Sjögren’s Syndrome by Regulating BAFF and Fas Expressions

Fangchinoline Inhibited Proliferation of Neoplastic B-lymphoid Cells and Alleviated Sjögren's Syndrome-like Responses in NOD/Ltj Mice via the Akt/mTOR Pathway

AutoDock and molecular dynamics-based therapeutic potential prediction of flavonoids for primary Sjögren's syndrome

Mucosal administration of α-fodrin inhibits experimental Sjögren's syndrome autoimmunity

Modulation of LPS-mediated Inflammation by Fenofibrate Via the TRIF-dependent TLR4 Signaling Pathway in Vascular Smooth Muscle Cells.

PPARα Agonist Fenofibrate Improves Diabetic Nephropathy in Db/db Mice

Total Glucosides of Paeony (TGP) Alleviates Sjogren's Syndrome Through Inhibiting Inflammatory Responses in Mice.

Fenofibrate Enhances the in Vitro Differentiation of Foxp3+ Regulatory T Cells in Mice